Laminin alpha2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice
- PMID: 12609502
- DOI: 10.1016/s0960-8966(02)00266-3
Laminin alpha2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice
Abstract
Deficiency of laminin alpha2 is the cause of one of the most severe muscular dystrophies in humans and other species. It is not yet clear how particular mutations in the laminin alpha2 chain gene affect protein expression, and how abnormal levels or structure of the protein affect disease. Animal models may be valuable for such genotype-phenotype analysis and for determining mechanism of disease as well as function of laminin. Here, we have analyzed protein expression in three lines of mice with mutations in the laminin alpha2 chain gene and in two lines of transgenic mice overexpressing the human laminin alpha2 chain gene in skeletal muscle. The dy(3K)/dy(3K) experimental mutant mice are completely deficient in laminin alpha2; the dy/dy spontaneous mutant mice have small amounts of apparently normal laminin; and the dy(W)/dy(W) mice express even smaller amounts of a truncated laminin alpha2, lacking domain VI. Interestingly, all mutants lack laminin alpha2 in peripheral nerve. We have demonstrated previously, that overexpression of the human laminin alpha2 in skeletal muscle in dy(2J)/dy(2J) and dy(W)/dy(W) mice under the control of a striated muscle-specific creatine kinase promoter substantially prevented the muscular dystrophy in these mice. However, dy(W)/dy(W) mice, expressing the human laminin alpha2 under the control of the striated muscle-specific portion of the desmin promoter, still developed muscular dystrophy. This failure to rescue is apparently because of insufficient production of laminin alpha2. This study provides additional evidence that the amount of laminin alpha2 is most critical for the prevention of muscular dystrophy. These data may thus be of significance for attempts to treat congenital muscular dystrophy in human patients.
Similar articles
-
Laminin α1 reduces muscular dystrophy in dy2J mice.Matrix Biol. 2018 Sep;70:36-49. doi: 10.1016/j.matbio.2018.02.024. Epub 2018 Mar 12. Matrix Biol. 2018. PMID: 29544677
-
Spontaneous muscular dystrophy caused by a retrotransposal insertion in the mouse laminin alpha2 chain gene.Neuromuscul Disord. 2003 Mar;13(3):216-22. doi: 10.1016/s0960-8966(02)00278-x. Neuromuscul Disord. 2003. PMID: 12609503
-
Elimination of myostatin does not combat muscular dystrophy in dy mice but increases postnatal lethality.Am J Pathol. 2005 Feb;166(2):491-7. doi: 10.1016/S0002-9440(10)62271-7. Am J Pathol. 2005. PMID: 15681832 Free PMC article.
-
Merosin and congenital muscular dystrophy.Microsc Res Tech. 2000 Feb 1-15;48(3-4):181-91. doi: 10.1002/(SICI)1097-0029(20000201/15)48:3/4<181::AID-JEMT6>3.0.CO;2-Q. Microsc Res Tech. 2000. PMID: 10679965 Review.
-
The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review.J Med Genet. 2001 Oct;38(10):649-57. doi: 10.1136/jmg.38.10.649. J Med Genet. 2001. PMID: 11584042 Free PMC article. Review.
Cited by
-
A Family of Laminin α2 Chain-Deficient Mouse Mutants: Advancing the Research on LAMA2-CMD.Front Mol Neurosci. 2020 Apr 21;13:59. doi: 10.3389/fnmol.2020.00059. eCollection 2020. Front Mol Neurosci. 2020. PMID: 32457577 Free PMC article. Review.
-
Extracellular Control of Radial Glia Proliferation and Scaffolding During Cortical Development and Pathology.Front Cell Dev Biol. 2020 Oct 16;8:578341. doi: 10.3389/fcell.2020.578341. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33178693 Free PMC article. Review.
-
Transgenic Rescue of the LARGEmyd Mouse: A LARGE Therapeutic Window?PLoS One. 2016 Jul 28;11(7):e0159853. doi: 10.1371/journal.pone.0159853. eCollection 2016. PLoS One. 2016. PMID: 27467128 Free PMC article.
-
Dual transgene amelioration of Lama2-null muscular dystrophy.Matrix Biol. 2023 Apr;118:1-15. doi: 10.1016/j.matbio.2023.03.001. Epub 2023 Mar 5. Matrix Biol. 2023. PMID: 36878377 Free PMC article.
-
Laminin and Integrin in LAMA2-Related Congenital Muscular Dystrophy: From Disease to Therapeutics.Front Mol Neurosci. 2020 Feb 11;13:1. doi: 10.3389/fnmol.2020.00001. eCollection 2020. Front Mol Neurosci. 2020. PMID: 32116540 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases